The new nanobody is expected to be used in the treatment of schizophrenia.

The French National Center for Scientific Research recently issued a statement saying that an international team of researchers, including those from the institution, has designed a new type of nano-antibody that can be injected with fewer side effects using antibodies derived from alpacas, opening up a new pathway for the treatment of schizophrenia. The related research results have been published in the British journal Nature. According to the statement, current treatment methods for schizophrenia can alleviate certain symptoms, but have limited effects on cognitive impairments that affect patients' daily lives. This new nano-antibody can specifically activate the glutamate receptors that regulate neuronal activity, which are key receptors in the brain related to schizophrenia, and may be used for the treatment of schizophrenia.